Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.14 - $54.23
Previous CloseN/A
Volume92.82K
Average Volume (3M)544.07K
Market Cap
$2.31B
Enterprise Value$1.90B
Total Cash (Recent Filing)$222.50M
Total Debt (Recent Filing)$317.76M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 01, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding49,014,190
10 Day Avg. Volume496,932
30 Day Avg. Volume544,068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.84
Price to Cash Flow (P/CF)-113.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.43
Enterprise Value/Ebitda-38.73
Forecast
1Y Price Target
$65.29Price Target Upside41.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMirum achieved positive operating cash flow and expects to continue this trend in 2025.
Product ExpansionFDA approval of CTEXLI allows Mirum to market directly to patients with cerebrotendinous xanthomatosis, potentially increasing the number of diagnosed patients.
Bears Say
Market CompetitionLivmarli revenue continues its growth and outperforms competitive iBAT inhibitor Bylvay.
Regulatory ChallengesVolixibat's Phase 2 VISTAS study nearing completion could support regulatory filings if data is positive.
---
Ownership Overview
9.43% Insiders
24.44% Mutual Funds
40.60% Other Institutional Investors
13.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $54.23 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $2.31B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is May 01, 2025 which is in 35 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Feb 26, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.258 by -$0.232.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.31.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 49,014,190 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.258. Following the earnings report the stock price went down -7.007%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
---
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.29 (41.08% Upside)
$65.29 (41.08% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 77%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 73.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.71%
12-Months-Change
Fundamentals
Return on Equity
-37.08%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases. The company primarily operates in the healthcare and pharmaceuticals sector, with a strong emphasis on rare liver conditions. Its core products include treatments aimed at alleviating conditions such as Alagille syndrome and progressive familial intrahepatic cholestasis, offering transformative solutions to patients with high unmet medical needs.
---
MIRM Company Deck
---
MIRM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Mirum Pharmaceuticals demonstrated significant financial growth and strong pipeline advancements, with notable achievements including the approval of CTEXLI and the expansion of LIVMARLI's market. However, high operating expenses and challenges in fully penetrating the Alagille syndrome market were noted. The positive aspects of financial performance and pipeline progress outweigh the challenges, indicating a strong outlook for the company.Read More>---
MIRM Stock 12 Month Forecast
Average Price Target
$65.29
▲(41.08% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Novartis
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
31/35 ratings generated profit
1 Year Average Return
+33.26%
reiterated a buy rating 30 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 88.57% of your transactions generating a profit, with an average return of +33.26% per trade.
---